DalsnaFinance Account

Medtronic $MDT

Health Care · Health Care Equipment · NYSE/NASDAQ

S&P 500 Russell 1000 Ireland

Create a scorecard

$94.23

+1.22 (+1.31%)

As of Oct 15, 2026, 12:26 AM EDT

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Sep 1, 2026, the first target we tracked for MDT.

Medtronic (MDT) is trading up at $94.23 (+1.31%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on MDT

Current price targets from 4 firms average $106, median $107, ranging from $95 to $115 — the average is 12% above the current $94.2. Each is tracked to its date and scored the same way a member's call is.

Mizuho $92.2 → $115 by Sep 2027 Outperform Sep 2, 2026 via Investing.com · Mizuho's track record
Stifel $92.2 → $95 by Sep 2027 Hold Sep 2, 2026 via Investing.com · Stifel's track record
Needham $92 → $114 by Sep 2027 Buy Sep 1, 2026 via Investing.com · Needham's track record
BTIG $92 → $100 by Sep 2027 Buy Sep 1, 2026 via Investing.com · BTIG's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Medtronic revenue & net income history (FY2017–FY2026)

RevenueNet incomeNet margin (right axis, %)

Medtronic annual financial statements
	FY2017Apr 2017	FY2018Apr 2018	FY2019Apr 2019	FY2020Apr 2020	FY2021Apr 2021	FY2022Apr 2022	FY2023Apr 2023	FY2024Apr 2024	FY2025Apr 2025	FY2026Apr 2026
Income statement
Revenue	$29.7B	$30.0B	$30.6B	$28.9B	$30.1B	$31.7B	$31.2B	$32.4B	$33.5B	$36.4B
Growth (year over year)	+3.0%	+0.8%	+2.0%	−5.4%	+4.2%	+5.2%	−1.4%	+3.6%	+3.6%	+8.4%
Gross profit	$20.4B	$20.9B	$21.4B	$19.5B	$19.6B	$21.5B	$20.5B	$21.1B	$21.9B	$23.6B
Gross margin	68.7%	69.8%	70.0%	67.4%	65.2%	68.0%	65.7%	65.3%	65.3%	65.0%
Operating income	$5.38B	$6.64B	$6.27B	$4.79B	$4.48B	$5.75B	$5.49B	$5.14B	$5.96B	$6.47B
Operating margin	18.1%	22.2%	20.5%	16.6%	14.9%	18.2%	17.6%	15.9%	17.8%	17.8%
Net income	$4.03B	$3.10B	$4.63B	$4.79B	$3.61B	$5.04B	$3.76B	$3.68B	$4.66B	$4.80B
Net margin	13.6%	10.4%	15.2%	16.6%	12.0%	15.9%	12.0%	11.4%	13.9%	13.2%
EPS (diluted)	$2.89	$2.27	$3.41	$3.54	$2.66	$3.73	$2.82	$2.76	$3.61	$3.73
Balance sheet
Cash and equivalents	$4.97B	$3.67B	$4.39B	$4.14B	$3.59B	$3.71B	$1.54B	$1.28B	$2.22B	$1.95B
Total assets	$99.9B	$91.4B	$89.7B	$90.7B	$93.1B	$91.0B	$90.9B	$90.0B	$91.7B	$93.0B
Total liabilities	$49.5B	$40.6B	$39.5B	$39.8B	$41.5B	$38.3B	$39.3B	$39.6B	$43.4B	$43.0B
Long-term debt	$25.9B	$23.7B	$24.6B	$22.1B	$26.4B	$20.4B	$24.3B	$23.9B	$25.6B	$26.2B
Shareholders' equity	$50.2B	$50.7B	$50.1B	$50.7B	$51.4B	$52.6B	$51.5B	$50.2B	$48.0B	$49.5B
Cash flow
Operating cash flow	$6.88B	$4.68B	$7.01B	$7.23B	$6.24B	$7.35B	$6.04B	$6.79B	$7.04B	$7.33B
Capital expenditure	$1.25B	$1.07B	$1.13B	$1.21B	$1.35B	$1.37B	$1.46B	$1.59B	$1.86B	$1.90B
Free cash flow	$5.63B	$3.62B	$5.87B	$6.02B	$4.88B	$5.98B	$4.58B	$5.20B	$5.18B	$5.43B
Dividends paid	$2.38B	$2.49B	$2.69B	$2.89B	$3.12B	$3.38B	$3.62B	$3.67B	$3.59B	$3.64B
Share buybacks	$3.54B	$2.17B	$2.88B	$1.33B	$652.0M	$2.54B	$645.0M	$2.14B	$3.23B	$1.03B

RevenueNet incomeNet margin (right axis, %)

Medtronic quarterly financial statements
	Q2 FY25Oct 2024	Q3 FY25Jan 2025	Q4 FY25^†Apr 2025	Q1 FY26Jul 2025	Q2 FY26Oct 2025	Q3 FY26Jan 2026	Q4 FY26^†Apr 2026	Q1 FY27Jul 2026
Income statement
Revenue	$8.40B	$8.29B	$8.93B	$8.58B	$8.96B	$9.02B	$9.81B	$9.76B
Growth (year over year)	+5.2%	+2.5%	+3.9%	+8.4%	+6.6%	+8.7%	+9.9%	+13.7%
Gross profit	$5.46B	$5.51B	$5.78B	$5.58B	$5.90B	$5.76B	$6.41B	$6.34B
Gross margin	64.9%	66.5%	64.8%	65.0%	65.8%	63.8%	65.4%	65.0%
Operating income	$1.59B	$1.65B	$1.44B	$1.45B	$1.69B	$1.46B	$1.87B	$1.76B
Operating margin	19.0%	19.9%	16.1%	16.8%	18.8%	16.2%	19.1%	18.1%
Net income	$1.27B	$1.29B	$1.06B	$1.04B	$1.37B	$1.14B	$1.24B	$1.47B
Net margin	15.1%	15.6%	11.8%	12.1%	15.3%	12.7%	12.7%	15.1%
EPS (diluted)	$0.99	$1.01	$0.81	$0.81	$1.07	$0.89	$0.96	$1.14
Balance sheet
Cash and equivalents	$1.39B	$1.24B	$2.22B	$1.27B	$1.28B	$1.15B	$1.95B	$1.69B
Total assets	$90.0B	$90.0B	$91.7B	$91.0B	$91.3B	$91.5B	$93.0B	$93.3B
Total liabilities	$41.3B	$40.4B	$43.4B	$42.8B	$42.5B	$42.3B	$43.0B	$42.5B
Long-term debt	$24.6B	$24.0B	$25.6B	$26.2B	$27.7B	$27.9B	$26.2B	$25.6B
Shareholders' equity	$48.5B	$49.4B	$48.0B	$47.9B	$48.7B	$49.0B	$49.5B	$50.2B
Cash flow
Operating cash flow	$958.0M	$2.57B	$2.53B	$1.09B	$925.0M	$2.74B	$2.57B	$1.79B
Capital expenditure	$404.0M	$476.0M	$459.0M	$504.0M	$468.0M	$444.0M	$488.0M	$503.0M
Free cash flow	$554.0M	$2.10B	$2.07B	$584.0M	$457.0M	$2.30B	$2.08B	$1.29B
Dividends paid	$897.0M	$897.0M	$897.0M	$910.0M	$910.0M	$911.0M	$908.0M	$921.0M
Share buybacks	$288.0M	$181.0M	$274.0M	$123.0M	$372.0M	$105.0M	$435.0M	$267.0M

From Medtronic's 10-K and 10-Q filings with the SEC; its fiscal year ends in April. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Medtronic

Medtronic plc is an American-Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies. It is one of the biggest medical tech companies in the world and is currently the largest medical device company in the world by revenue.

Source: Wikipedia — Medtronic